Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	37.34	33.79	43.05	65.47	112.35	4.21
Short-Term Investments	25.29	35.71	24.69	17.38	-	-
Cash & Short-Term Investments	62.63	69.5	67.74	82.85	112.35	4.21
Cash Growth	18.81%	2.60%	-18.24%	-26.26%	2566.65%	30.96%
Accounts Receivable	7.85	10.18	16.12	7.19	1.42	2.44
Other Receivables	4.77	0.33	1.26	1.11	0.11	0.14
Receivables	12.62	10.51	17.38	8.3	1.53	2.58
Inventory	2.56	1.97	-	-	-	-
Prepaid Expenses	3.77	4.05	1.82	1.69	0.89	0.66
Restricted Cash	-	-	-	-	-	0.11
Other Current Assets	-	-	-	-	0.29	0.83
Total Current Assets	81.57	86.03	86.94	92.83	115.06	8.38
Property, Plant & Equipment	2.06	1.01	1.53	1.78	2.03	2.39
Long-Term Investments	6.09	6.01	-	20	15.42	-
Goodwill	4.7	4.7	4.7	-	-	-
Other Intangible Assets	67.38	68.99	69.23	-	-	-
Long-Term Accounts Receivable	-	-	-	-	-	0.4
Other Long-Term Assets	10.91	11.38	9.94	0.72	0.44	0.04
Total Assets	172.71	178.13	172.33	115.34	132.94	11.21
Accounts Payable	17.82	13.08	13.99	3.61	0.52	1.17
Accrued Expenses	5.17	17.37	18.97	7.21	2.52	5.47
Short-Term Debt	-	-	37.7	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	-	0.39
Current Portion of Leases	0.59	0.42	0.54	0.49	0.37	0.5
Other Current Liabilities	3.4	3.2	2.52	0.71	0.82	-
Total Current Liabilities	26.98	34.07	73.72	12.02	4.23	7.54
Long-Term Debt	60.09	59.5	5.07	12.8	-	68.05
Long-Term Leases	1.16	0.37	0.46	0.84	1.24	1.61
Other Long-Term Liabilities	43.46	44.52	31.22	14.55	0.36	0.43
Total Liabilities	131.69	138.46	110.46	40.22	5.82	77.62
Common Stock	0.01	0.01	0	0	0	-
Additional Paid-In Capital	560.47	555.3	472.66	436.27	396.96	192.06
Retained Earnings	-508.39	-505.29	-399.78	-353.73	-267.03	-258.47
Treasury Stock	-10.98	-10.98	-10.98	-7.54	-2.81	-
Comprehensive Income & Other	-0.08	0.63	-0.04	0.11	-	-
Total Common Equity	41.02	39.67	61.86	75.12	127.12	-66.41
Shareholders' Equity	41.02	39.67	61.86	75.12	127.12	-66.41
Total Liabilities & Equity	172.71	178.13	172.33	115.34	132.94	11.21
Total Debt	61.84	60.3	43.77	14.13	1.61	70.55
Net Cash (Debt)	0.79	9.2	23.97	68.72	110.74	-66.33
Net Cash Growth	-90.58%	-61.62%	-65.11%	-37.95%	-	-
Net Cash Per Share	0.02	0.20	0.68	1.99	3.72	-16.66
Filing Date Shares Outstanding	54.68	54.12	41.85	34.54	34.42	28.38
Total Common Shares Outstanding	54.68	53.67	41.53	34.54	35.01	4.54
Working Capital	54.6	51.96	13.22	80.81	110.83	0.85
Book Value Per Share	0.75	0.74	1.49	2.17	3.63	-14.64
Tangible Book Value	-31.06	-34.03	-12.06	75.12	127.12	-66.41
Tangible Book Value Per Share	-0.57	-0.63	-0.29	2.17	3.63	-14.64
Machinery	-	1.36	1.51	1.28	1.05	1.01
Leasehold Improvements	-	0.71	0.71	0.71	0.72	0.72

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q